ArticleEndocrinology, diabetes & metabolism2018
The new FreeStyle libre flash glucose monitoring system improves the glycaemic control in a cohort of people with type 1 diabetes followed in real-life conditions over a period of one year.
Article in Endocrinology, diabetes & metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Guideline
- Effects of real-time continuous glucose monitoring in type 1 diabetes: a meta-analysis of randomized controlled trials.Acta diabetologica · 2021Pooled it
- Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis.BMJ open diabetes research & care · 2020Pooled it
- Trial
- Effects of a Diabetes Self-Management Education Program on Glucose Levels and Self-Care in Type 1 Diabetes: A Pilot Randomized Controlled Trial.International journal of environmental research and public health · 2022Trial
- Trial
- Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial.BMJ open diabetes research & care · 2020Trial
- The efficacy of intermittent scanning continuous glucose monitoring in the elderly: A case-control study.Diabetes, obesity & metabolism · 2025Observational
- Advances in Continuous Glucose Monitoring: Clinical Applications.Endocrinology and metabolism (Seoul, Korea) · 2025Review
- Glycemic metrics in Japanese isCGM users - Analysis by diabetes type and therapy.Journal of diabetes investigation · 2024Article
- All Children Deserve to Be Safe, Mothers Too: Evidence and Rationale Supporting Continuous Glucose Monitoring Use in Gestational Diabetes Within the Medicaid Population.Journal of diabetes science and technology · 2024Review
- Increase Access, Reduce Disparities: Recommendations for Modifying Medicaid CGM Coverage Eligibility Criteria.Journal of diabetes science and technology · 2024Article
- Evaluating the precision and reliability of real-time continuous glucose monitoring systems in ambulatory settings: a systematic review.Therapeutic advances in endocrinology and metabolism · 2024Review
- Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus.Diabetes care · 2023Review
- Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus.Clinical chemistry · 2023Article
- The use of isCGM leads to marked reduction in severe hypoglycemia requiring emergency medical service or hospital admission and diabetic ketoacidosis in adult type 1 diabetes patients.Acta diabetologica · 2023Article
- Personalized Virtual Care Using Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Less Intensive Therapies.Clinical diabetes : a publication of the American Diabetes Association · 2023Article
- Validity of Danish public criteria for providing flash glucose monitoring to participants with type 1 diabetes-An explorative cohort study.Endocrinology, diabetes & metabolism · 2022Article
- The Frequency of Intermittently Scanned Glucose and Diurnal Variation of Glycemic Metrics.Journal of diabetes science and technology · 2022Article
- The Association of Personality Traits and Parameters of Glycemic Regulation in Type 1 Diabetes Mellitus Patients Using isCGM.Healthcare (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsUsing the novel FreeStyle Libre (FSL), glucose monitoring (FGM) system becomes increasingly popular among people with type 1 diabetes (T1D) and is associated with less and shorter hypoglycaemic events without deterioration of HbA1c. There are not yet data reporting the impact of FGM in people with T1D in real-life conditions. We sought of evaluating the tolerance, the acceptance and the efficacy of the FGM system in routine medical practice.
methodsThis 12-month observational study included 120 individuals with T1D evaluated every 3 months. After having been instructed about FGM utilization, participants were trained to optimize the glycaemic control.
resultsParticipants stopped immediately of measuring capillary blood glucose (2.88 ± 0.12 per day) (mean ± SEM) after having received the first FSL device and the number of scans per day increased up to 8.87 ± 0.58 per day. HbA1c levels decreased from 8.51% ± 0.14% at baseline to 7.77% ± 0.09% after 3 months to slightly increase to 7.92% ± 0.09% at 12 months, in correlation with the number of scans per day. The number (but not the duration) of hypoglycaemic events slightly increased from 16.9 ± 1.44 per month at baseline to 24.0 ± 2.91 per month at 12 months, after reaching a peak of 26.4 ± 2.31 per month at 6 months. They were correlated with improved HbA1c.
conclusionOur study shows that using the FGM system improves HbA1c levels in people with T1D along with a moderate increase in the number of mild hypoglycaemic events. The new FGM system facilitates the therapeutic empowerment of people with T1D, but in a context of structured education.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.